Read on Twitter
Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the 3-4 months following recovery from infection with #SARSCoV2 (1/9): https://www.medrxiv.org/content/10.1101/2020.08.06.20169367v1
To do this, @khdcrawford measured neutralizing antibody titers in longitudinal samples that @HelenChuMD's group had collected from 34 recovered individuals, whose infections ranged from asymptomatic to severe disease. (2/9)
This plot shows the dynamics for just one individual who is pretty typical: neutralizing antibody titers peak 3-4 weeks post-symptom onset, and then decline somewhat in the months following that. (See Fig 1A of pre-print for comparable data for all 34 individuals.) (3/9)
On average, the neutralizing titers at 3-4 months post-symptom onset are about 4-fold lower than their peak at one month post-symptom onset. (4/9)
Importantly, we do NOT think this modest decline in titers in first 3-4 months is alarming. Antibodies are expected to decline somewhat from their peak following acute infection, and often reach a stable plateau. See this tweet from @SCOTTeHENSLEY (5/9) https://twitter.com/SCOTTeHENSLEY/status/1285626936325279748
Of course, we can't yet be certain about durability of antibodies to #SARSCoV2 over longer times. For that, future studies need to look at serum antibodies at longer times, & long-lived plasma and memory B cells. (6/9)
Our paper also makes a few other observations that concord w findings others have reported: binding antibodies to Spike and RBD measured by ELISA (by @adingens @KingLabIPD) correlate w neutralizing titers/... (7/9)
... patients w severe disease have higher initial neut titers, but (this is new) at later times the titers are similar across disease severity; IgG binding titers maintained better than IgA, IgM.
Finally, ours is just one of several recent studies looking at antibody... (8/9)
Finally, ours is just one of several recent studies looking at antibody... (8/9)
... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See also: (9/9)
https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1
https://www.medrxiv.org/content/10.1101/2020.07.18.20156810v1
https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v1
https://www.biorxiv.org/content/10.1101/2020.07.09.194639v1
https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1 https://www.medrxiv.org/content/10.1101/2020.07.21.20159178v1
https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1
https://www.medrxiv.org/content/10.1101/2020.07.18.20156810v1
https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v1
https://www.biorxiv.org/content/10.1101/2020.07.09.194639v1
https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1 https://www.medrxiv.org/content/10.1101/2020.07.21.20159178v1
